# Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC

> **NCT07296705** · PHASE2 · RECRUITING · sponsor: **Fujian Medical University Union Hospital** · enrollment: 25 (estimated)

## Conditions studied

- Muscle Invasive Bladder Cancer (MIBC)

## Interventions

- **DRUG:** Zanidatamab
- **DRUG:** Tislelizumab
- **DRUG:** Cisplatin
- **DRUG:** Gemcitabine
- **DRUG:** Nab-paclitaxel

## Key facts

- **NCT ID:** NCT07296705
- **Lead sponsor:** Fujian Medical University Union Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-25
- **Primary completion:** 2027-12
- **Final completion:** 2029-12
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-12-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07296705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07296705, "Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC". Retrieved via AI Analytics 2026-05-19 from https://api.ai-analytics.org/clinical/NCT07296705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*